Table 5.
Adjusted Means, 95% Confidence Intervals of Efficacy and Tolerability Outcomes by CYP2D6 and CYP2C19 Subgroups
| |
Adjusted means (95% CI)a |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| |
CYP2D6-predicted metabolizing phenotype (n = 255) |
CYP2C19-predicted metabolizing phenotype (n = 127) |
|||||||
| PM (n = 45) | IM (n = 56) | EM (n = 137) | UM (n = 17) | p value | PM (n = 11) | IM (n = 34) | EM (n = 82) | p value | |
| Efficacy Outcomes | |||||||||
| Behavioral Intervention Score | 0.20 (0.03–0.41) | 0.32 (0.18–0.48) | 0.45 (0.30–0.62) | 0.60 (0.37–0.86) | 0.01 | 0.42 (0.06–0.91) | 0.54 (0.29–0.85) | 0.40 (0.23–0.59) | 0.57 |
| Number of PRN doses | 1.01 (0.53–1.66) | 1.22 (0.82–1.72) | 1.45 (1.02–1.98) | 1.71 (1.09–2.52) | 0.14 | 1.33 (0.28–3.26) | 1.15 (0.41–2.28) | 1 (0.41–1.84) | 0.81 |
| Length of stay | 6.14 (5.18–7.28) | 6.41 (7.24–8.04) | 6.68 (7.53–8.48) | 6.97 (8.19–9.93) | 0.30 | 7.04 (4.74–10.5) | 7.11 (5.58–9.05) | 6.70 (5.63–7.96) | 0.88 |
| Change of GAF | 22.7 (20.8–24.5) | 22.7 (21.4–24.0) | 22.7 (21.4–23.9) | 22.7 (21.0–24.4) | 0.98 | 23.4 (19.4–27.3) | 25.9 (23.2–28.7) | 25.2 (22.9–27.6) | 0.41 |
| Tolerability outcome | |||||||||
| Number of ADRs | 1.27 (0.81–1.85) | 1.14 (0.81–1.52) | 1.01 (0.72–1.36) | 0.89 (0.53–1.35) | 0.27 | 2.04 (0.95–3.73) | 1.07 (0.58–1.71) | 0.67 (0.37–1.02) | 0.01 |
Data presented as adjusted means and 95% confidence interval (CI) with adjusters set at the mean or reference category (sex = female, age = 13, admit GAF = 20, number of psychiatric drugs = 2, psychotic disorder = no, anxiety disorder = no, impulse control disorder = no, pervasive developmental disorder = no).
Abbreviations: PM = Individual gene predicted poor metabolizing phenotype; IM = individual gene predicted intermediate metabolizing phenotype; EM = individual gene predicted extensive metabolizing phenotype; UM = individual gene predicted ultra-rapid metabolizing phenotype; PRN = as needed; GAF = Global Assessment of Functioning score; ADRs = adverse drug reactions.